Navratilova Melfia, Suradi, Sutanto
SMF Pulmonologi dan Kedokteran Respirasi, Fakultas Kedokteran Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta
Abstract
Background: Treatment of asthma is to achieve controled asthma. Decline in a proinflamatory asthma cytokine, interleukin-4 (IL-4) serum improve lung function in order to reach the level of asthma control. Omega 3 suppress the secretion of proinflammatory cytokines by reducing mast cell degranulation thus giving Omega 3 lowers serum levels of IL-4 and increasing FEV1. This study aims to determine and analyze the effect of Omega 3 in the serum levels of IL-4 and FEV1.
Methods: This study was carried out clinical trials of pre-posttest control design. Subjects were outpatient with asthma at Pulmonology Clinic Hospital Dr. Moewardi Surakarta on October 16 until December 3, 2015 as many as 30 subjects, with 15 subjects who were given treatment group Omega 3 and the standard therapy of asthma and 15 patients as the control group were only giving with Omega 3.
Results: Omega 3 treatment increases the serum levels of IL-4 with the difference of treatment group was lower than control group (0,0100 + 0,02726 vs 0,0153 ± 0,7947, p = 0,440). No significant found of FEV1 after treatment by Omega 3 with the difference of the treatment group was higher than the control group (2,70 ± 4,92 vs 0,79 ± 8,07, p = 0.688).
Conclusion: There is no effect of Omega 3 to decreasing IL-4 serum levels and no significant increasing FEV1 of asthmatic patients. (J Respir Indo. 2016; 36: 94-9)
Keywords: Omega 3, Serum Levels of IL-4, FEV1, Asthma